- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04215354
Association Between Fatigue and Balance in Patients With Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Electromagnetic field significantly reduced fatigue level in patients with MS.This effect reflected significantly on other symptoms such as balance, depression, disease severity and the quality of life in those patients.
Virtual reality program significantly improving balance and balance perception .Virtual reality program also improved quality of life by improving general health, physical function and decreasing physical limitation significantly. However, Virtual reality programs did not improve fatigue.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Eastern
-
Dammam, Eastern, Saudi Arabia, 2435 Dammam 31451
- Imam Abdulrahman Bin Faisal University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Relapsing remitting type of MS.
- Age between 20-50 years.
- Ambulatory with or without an device.
- Complaining of fatigue, Have a score of 4/10 or more on the fatigue visual analogue scale in last four weeks
Exclusion Criteria:
- An acute episode of MS within the last 30 days.
- Pregnancy at any stage.
- Severely blurred vision.
- A pacemaker.
- Epilepsy of any type.
- Recent organ transplant.
- Cardiac arrhythmia.
- Large aneurysm.
- Heavy psychosis.
- Otitis media in last 2 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MAGNET GROUP
Patients were exposed to very low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional using magnet mattress.
|
Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA).
Mattress which is flexible, 6 flat coil was used for whole body therapy.
Other Names:
|
Experimental: VIRTUAL REALITY
Balance training was done using the Wii Fit plus machine which required balance board .Using video game console designed by Nintendo. The program consisted of three games: soccer heading, ski slalom and table tilt. |
Wii Fit plus machine which required balance board .
It is a video game console designed by Nintendo 2009
Other Names:
|
Active Comparator: PLACEBO
Patients in the placebo group had identical program to magnet group.
They were asked to lie down in the magnet mattress; however, the magnet was not switched on and the patient doesn't know (blind).
|
Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA).
Mattress which is flexible, 6 flat coil was used for whole body therapy.
Other Names:
|
No Intervention: HEALTHY SUBJECT
healthy subjects with age, gender and BMI matched with the patients with MS were recruited to participate in the study.
This group was recruited to establish the normal balance and fatigue parameters.
Subjects in this group sign the consent form of healthy subjects and all measurement was taken as balance, fatigue, depression, quality of life and urinary incontinence screening questionnaire.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Fatigue Impact Scale
Time Frame: 12 weeks.
|
It is a 21 items standardized questionnaire.
Each item has five levels of response (range from 0 - 4).
The total score ranges from 0 (no impact of fatigue) better condition to 84 (maximum impact of fatigue)worse condition.
|
12 weeks.
|
Balance
Time Frame: 12 weeks.
|
Berg Balance Scale (BBS)range from 0(worse condition) to 56(better condition)
|
12 weeks.
|
balance confidence
Time Frame: 12 weeks.
|
Activities- specific Balance Confidence scale .it is 16 items ofvisual analogue scale from 0-100%.score from 0 minimum confidence (worse condition) to 1600 maximum score (better condition).
|
12 weeks.
|
Depression (Beck depression inventory ii (BDI-II))
Time Frame: 12 weeks.
|
It is 21 questions with each item range from 0 (normal) to 3 (most severe) with a maximum score of 63 (worse condition).The total score of the scale was used to classify patients as follows: normal (1-10), mild mood disturbance (11-16), border line of depression (17-20), moderate depression (21-30), severe depression (31-40), extreme depression (over 40)
|
12 weeks.
|
Static balance using posturography,
Time Frame: 12 weeks
|
stability levels range from 1 to 10, with 10 being the most stable or least difficult to perform.
Static balance was measured at three different levels of stability; high level 8, medium 5 and low level 2. These levels where chosen to test patient balance on varying degree of instability.Patient who was unable to do the test due to sever balance impairment was given a score of 5000 based on the manufacturer recommendations in the machine manual (maximum score can subject got) which mean sever imbalance.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life measurement (Short Form 36 (SF-36)
Time Frame: 12 weeks.
|
The SF-36 consists of eight scaled scores as vitality (energy/fatigue), physical functioning, bodily pain, general health perceptions, and physical role functioning, emotional role functioning, social role functioning and mental health.each
item is scored from 0-100 for total 1800.
The lower the score the more the disability.
The higher the score the less disability.
|
12 weeks.
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-2014-04-319
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Magnetic field
-
Kyoto UniversityCompleted
-
Weill Medical College of Cornell UniversityCompletedTreatment Resistant DepressionUnited States
-
University of SevilleCompleted
-
Cardiovascular Therapy LLCUnknown
-
Neuromed IRCCSNot yet recruitingProgressive Multiple SclerosisItaly
-
University of CalgaryCompletedHealthy | PediatricsCanada
-
Mclean HospitalTerminatedBipolar Depression Depressed PhaseUnited States
-
National Center for Complementary and Integrative...CompletedRheumatoid Arthritis | MenopauseUnited States
-
Northern Orthopaedic Division, DenmarkUnknownChronic Venous Hypertension With Ulcer and Inflammation | Venous Ulcer PainDenmark
-
Tal Medical, Inc.CompletedDepressive Disorder | Depression | Depressive Disorder, Major | Depressive Disorder, Treatment-resistantUnited States